115 related articles for article (PubMed ID: 36512935)
1. CXCL11 negatively regulated by MED19 favours antitumour immune infiltration in breast cancer.
Zhang X; Wu J; Hu C; Zheng X; Guo Z; Li L
Cytokine; 2023 Feb; 162():156106. PubMed ID: 36512935
[TBL] [Abstract][Full Text] [Related]
2. Med19 promotes breast cancer cell proliferation by regulating CBFA2T3/HEB expression.
Zhang X; Fan Y; Liu B; Qi X; Guo Z; Li L
Breast Cancer; 2017 May; 24(3):433-441. PubMed ID: 27572702
[TBL] [Abstract][Full Text] [Related]
3. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
4. Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway.
Zhang X; Gao D; Fang K; Guo Z; Li L
Cancer Lett; 2019 Mar; 444():105-115. PubMed ID: 30583076
[TBL] [Abstract][Full Text] [Related]
5. Med19 is involved in chemoresistance by mediating autophagy through HMGB1 in breast cancer.
Liu B; Qi X; Zhang X; Gao D; Fang K; Guo Z; Li L
J Cell Biochem; 2019 Jan; 120(1):507-518. PubMed ID: 30161287
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of mediator subunit Med19 suppresses bladder cancer cell proliferation and migration by downregulating Wnt/β-catenin signalling pathway.
Yuan H; Yu S; Cui Y; Men C; Yang D; Gao Z; Zhu Z; Wu J
J Cell Mol Med; 2017 Dec; 21(12):3254-3263. PubMed ID: 28631286
[TBL] [Abstract][Full Text] [Related]
7. Lentivirus-mediated inhibition of Med19 suppresses growth of breast cancer cells in vitro.
Li LH; He J; Hua D; Guo ZJ; Gao Q
Cancer Chemother Pharmacol; 2011 Jul; 68(1):207-15. PubMed ID: 20890603
[TBL] [Abstract][Full Text] [Related]
8. Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.
Song C; Shang F; Tu W; Liu X
BMC Cancer; 2023 Mar; 23(1):296. PubMed ID: 37004015
[TBL] [Abstract][Full Text] [Related]
9. CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer.
Cao Y; Jiao N; Sun T; Ma Y; Zhang X; Chen H; Hong J; Zhang Y
Front Cell Dev Biol; 2021; 9():646252. PubMed ID: 33777950
[TBL] [Abstract][Full Text] [Related]
10. Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis.
Yu W; Zhang Z; Min D; Yang Q; Du X; Tang L; Lin F; Sun Y; Zhao H; Zheng S; He A; Li H; Yao Y; Shen Z
Eur J Cancer; 2014 Apr; 50(6):1125-36. PubMed ID: 24565852
[TBL] [Abstract][Full Text] [Related]
11. Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction.
Sun Y; Yang M; Zhang Q
Ann Transl Med; 2022 Dec; 10(24):1379. PubMed ID: 36660642
[TBL] [Abstract][Full Text] [Related]
12. Disruption of mediator complex subunit 19 (Med19) inhibits cell growth and migration in tongue cancer.
Zhu LJ; Yan WX; Chen ZW; Chen Y; Chen D; Zhang TH; Liao GQ
World J Surg Oncol; 2013 May; 11():116. PubMed ID: 23705783
[TBL] [Abstract][Full Text] [Related]
13. CXCL11-CXCR3 Axis Mediates Tumor Lymphatic Cross Talk and Inflammation-Induced Tumor, Promoting Pathways in Head and Neck Cancers.
Kumaravel S; Singh S; Roy S; Venkatasamy L; White TK; Sinha S; Glaser SS; Safe SH; Chakraborty S
Am J Pathol; 2020 Apr; 190(4):900-915. PubMed ID: 32035061
[TBL] [Abstract][Full Text] [Related]
14. Mediator Complex Subunit 19 Promotes the Development of Hepatocellular Carcinoma by Regulating the AKT/mTOR Signaling Pathway.
Zhang Y; Qin P; Xu X; Li M; Huang H; Yan J; Zhou Y
Front Oncol; 2021; 11():792285. PubMed ID: 35047403
[TBL] [Abstract][Full Text] [Related]
15. RAMP2-AS1 inhibits CXCL11 expression to suppress malignant phenotype of breast cancer by recruiting DNMT1 and DNMT3B.
Li L; Gan YP; Peng H
Exp Cell Res; 2022 Jul; 416(2):113139. PubMed ID: 35390315
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of Med19 suppresses proliferation and enhances chemo-sensitivity to cisplatin in non-small cell lung cancer cells.
Wei L; Wang XW; Sun JJ; Lv LY; Xie L; Song XR
Asian Pac J Cancer Prev; 2015; 16(3):875-80. PubMed ID: 25735376
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Mediator Complex Subunit 19 Suppresses the Growth and Invasion of Prostate Cancer Cells.
Yu S; Wang Y; Yuan H; Zhao H; Lv W; Chen J; Wan F; Liu D; Gao Z; Wu J
PLoS One; 2017; 12(1):e0171134. PubMed ID: 28125713
[TBL] [Abstract][Full Text] [Related]
18. MED19 promotes proliferation and tumorigenesis of lung cancer.
Sun M; Jiang R; Li JD; Luo SL; Gao HW; Jin CY; Shi DL; Wang CG; Wang B; Zhang XY
Mol Cell Biochem; 2011 Sep; 355(1-2):27-33. PubMed ID: 21519921
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer.
Liu Y; Tao X; Fan L; Jia L; Gu C; Feng Y
Mol Med Rep; 2012 Nov; 6(5):1050-6. PubMed ID: 22961438
[TBL] [Abstract][Full Text] [Related]
20. The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer.
He GY; Hu JL; Zhou L; Zhu XH; Xin SN; Zhang D; Lu GF; Liao WT; Ding YQ; Liang L
Br J Cancer; 2016 Nov; 115(11):1367-1378. PubMed ID: 27811858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
